For example, CD274 (PD-L1) gained wide attention in the last 2 years, and was used in clinical NSCLC immunotherapy38, LCN2 was reported to associate with the epithelial to mesenchymal transition39 and radioresistance in lung cancer40. Here, LCN2 is linked to non-small cell lung carcinoma.